Kyrgias George, Hajiioannou Jiannis, Tolia Maria, Kouloulias Vassilios, Lachanas Vasileios, Skoulakis Charalambos, Skarlatos Ioannis, Rapidis Alexandros, Bizakis Ioannis
Department of Radiotherapy/Radiation Oncology Department of Otolaryngology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Thessaly 2nd Department of Radiology-Radiotherapy Unit, ATTIKON University Hospital, Medical School, University of Athens Hellenic Anticancer Institute, St-Savvas Anticancer Hospital, Athens, Greece.
Medicine (Baltimore). 2016 Dec;95(50):e5035. doi: 10.1097/MD.0000000000005035.
Multimodality therapy constitutes the standard treatment of advanced and recurrent head and neck cancer. Since locoregional recurrence comprises a major obstacle in attaining cure, the role of intraoperative radiation therapy (IORT) as an add-on in improving survival and local control of the disease has been investigated. IORT allows delivery of a single tumoricidal dose of radiation to areas of potential residual microscopic disease while minimizing doses to normal tissues. Advantages of IORT include the conformal delivery of a large dose of radiation in an exposed and precisely defined tumor bed, minimizing the risk of a geographic miss creating the potential for subsequent dose reduction of external beam radiation therapy (EBRT). This strategy allows for shortening overall treatment time and dose escalation. The aim of this review is to summarize recent published work on the use of IORT as an adjuvant modality to treat common head and neck cancer in the primary or recurrent setting.
We searched the Medline, Scopus, Ovid, Cochrane, Embase, and ISI Web of Science databases for articles published from 1980 up to March 2016.
Based on relevant publications it appears that including IORT in the multimodal treatment may contribute to improved local control. However, the benefit in overall survival is not so clear.
IORT seems to be a safe, promising adjunct in the management of head and neck cancer and yet further well organized clinical trials are required to determine its role more precisely.
多模态治疗是晚期和复发性头颈癌的标准治疗方法。由于局部区域复发是实现治愈的主要障碍,术中放射治疗(IORT)作为一种辅助治疗手段在提高疾病生存率和局部控制率方面的作用已得到研究。IORT能够向潜在残留微小病灶区域单次给予杀灭肿瘤的放射剂量,同时将对正常组织的剂量降至最低。IORT的优势包括在暴露且精确界定的肿瘤床中适形给予大剂量放射,将遗漏照射区域的风险降至最低,从而有可能降低后续外照射放疗(EBRT)的剂量。这种策略有助于缩短总体治疗时间并提高剂量。本综述的目的是总结近期发表的关于在原发性或复发性头颈癌治疗中使用IORT作为辅助治疗手段的研究工作。
我们检索了Medline、Scopus、Ovid、Cochrane、Embase和ISI科学网数据库中1980年至2016年3月发表的文章。
基于相关出版物,在多模态治疗中纳入IORT似乎有助于提高局部控制率。然而,对总生存率的益处尚不明确。
IORT似乎是头颈癌治疗中一种安全且有前景的辅助治疗手段,但仍需要进一步开展组织完善的临床试验以更精确地确定其作用。